

# Michael Trauner

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/3005934/michael-trauner-publications-by-year.pdf>

**Version:** 2024-04-20

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

553  
papers

30,376  
citations

91  
h-index

155  
g-index

668  
ext. papers

36,877  
ext. citations

6.6  
avg, IF

7.31  
L-index

#	Paper	IF	Citations
553	Performance of noninvasive tests of fibrosis among Asians, Hispanic and non-Hispanic Whites in the STELLAR trials.. <i>Clinical Gastroenterology and Hepatology</i> , <b>2022</b> ,	6.9	1
552	Alterations of nitric oxide homeostasis as trigger of intestinal barrier dysfunction in non-alcoholic fatty liver disease.. <i>Journal of Cellular and Molecular Medicine</i> , <b>2022</b> ,	5.6	3
551	Factor VIII/protein C ratio independently predicts liver-related events but does not indicate a hypercoagulable state in ACLD.. <i>Journal of Hepatology</i> , <b>2022</b> ,	13.4	3
550	KIAA1363 affects retinyl ester turnover in cultured murine and human hepatic stellate cells.. <i>Journal of Lipid Research</i> , <b>2022</b> , 100173	6.3	1
549	Novel therapeutic targets for cholestatic and fatty liver disease. <i>Gut</i> , <b>2022</b> , 71, 194-209	19.2	7
548	Role of bile acids and their receptors in gastrointestinal and hepatic pathophysiology.. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2022</b> ,	24.2	5
547	Splenectomy ameliorates portal pressure and anemia in animal models of cirrhotic and non-cirrhotic portal hypertension.. <i>Advances in Medical Sciences</i> , <b>2022</b> , 67, 154-162	2.8	0
546	Comparison of Hepatic Tissue Characterization between T1-Mapping and Non-Contrast Computed Tomography. <i>Journal of Clinical Medicine</i> , <b>2022</b> , 11, 2863	5.1	
545	Risk of further decompensation/mortality in patients with cirrhosis and ascites as the first single decompensation event. <i>JHEP Reports</i> , <b>2022</b> , 100513	10.3	1
544	HCC risk stratification after cure of hepatitis C in patients with compensated advanced chronic liver disease. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	7
543	Antibiotic Therapy is Associated with Worse Outcome in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Journal of Hepatocellular Carcinoma</i> , <b>2021</b> , 8, 1485-1493	5.3	0
542	The prognostic value of HVPG-response to non-selective beta-blockers in patients with NASH cirrhosis and varices. <i>Digestive and Liver Disease</i> , <b>2021</b> ,	3.3	2
541	Prognosis of patients with hepatocellular carcinoma treated with immunotherapy - development and validation of the CRAFITY score. <i>Journal of Hepatology</i> , <b>2021</b> ,	13.4	17
540	Advancing the global public health agenda for NAFLD: a consensus statement. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2021</b> ,	24.2	37
539	Distinct structural and dynamic components of portal hypertension in different animal models and human liver disease etiologies. <i>Hepatology</i> , <b>2021</b> ,	11.2	1
538	Cirrhosis Regression is Associated with Improved Clinical Outcomes in Patients with Nonalcoholic Steatohepatitis. <i>Hepatology</i> , <b>2021</b> ,	11.2	7
537	Direct patient-physician communication via a hepatitis C hotline facilitates treatment initiation in patients with poor adherence. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 452-460	2.3	2

536	Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. <i>Gut</i> , <b>2021</b> , 70, 1758-1767	19.2	19
535	The Role of Lipid Sensing Nuclear Receptors (PPARs and LXR) and Metabolic Lipases in Obesity, Diabetes and NAFLD. <i>Genes</i> , <b>2021</b> , 12,	4.2	11
534	Influence of Genetic Variants on Disease Regression and Outcomes in HCV-Related Advanced Chronic Liver Disease after SVR. <i>Journal of Personalized Medicine</i> , <b>2021</b> , 11,	3.6	2
533	Intraperitoneal Activation of Coagulation and Fibrinolysis in Patients with Cirrhosis and Ascites. <i>Thrombosis and Haemostasis</i> , <b>2021</b> ,	7	1
532	Recent advances in the understanding and management of hepatorenal syndrome. <i>Faculty Reviews</i> , <b>2021</b> , 10, 48	1.2	1
531	Patterns of acute decompensation in hospitalized patients with cirrhosis and course of acute-on-chronic liver failure. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 427-437	5.3	3
530	The differential activation of cardiovascular hormones across distinct stages of portal hypertension predicts clinical outcomes. <i>Hepatology International</i> , <b>2021</b> , 15, 1160-1173	8.8	1
529	Diagnostic accuracy of non-invasive tests for advanced fibrosis in patients with NAFLD: an individual patient data meta-analysis. <i>Gut</i> , <b>2021</b> ,	19.2	31
528	Histone deacetylase 1 controls CD4 T cell trafficking in autoinflammatory diseases. <i>Journal of Autoimmunity</i> , <b>2021</b> , 119, 102610	15.5	3
527	COVID-19-Related Downscaling of In-Hospital Liver Care Decreased Patient Satisfaction and Increased Liver-Related Mortality. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1660-1675	6	4
526	A Machine Learning Approach Enables Quantitative Measurement of Liver Histology and Disease Monitoring in NASH. <i>Hepatology</i> , <b>2021</b> , 74, 133-147	11.2	20
525	Combined effects of PNPLA3, TM6SF2 and HSD17B13 variants on severity of biopsy-proven non-alcoholic fatty liver disease. <i>Hepatology International</i> , <b>2021</b> , 15, 922-933	8.8	6
524	Concentration of Gallbladder Phosphatidylcholine in Cholangiopathies: A Phosphorus-31 Magnetic Resonance Spectroscopy Pilot Study. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> ,	5.6	1
523	Safety of direct oral anticoagulants in patients with advanced liver disease. <i>Liver International</i> , <b>2021</b> , 41, 2159-2170	7.9	7
522	Decreasing von Willebrand Factor Levels Upon Nonselective Beta Blocker Therapy Indicate a Decreased Risk of Further Decompensation, Acute-on-chronic Liver Failure, and Death. <i>Clinical Gastroenterology and Hepatology</i> , <b>2021</b> ,	6.9	4
521	Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. <i>Annals of the Rheumatic Diseases</i> , <b>2021</b> , 80, 71-87	2.4	50
520	A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis. <i>Hepatology</i> , <b>2021</b> , 73, 1105-1116	11.2	2
519	Alpha-fetoprotein-adjusted-to-HCC-size criteria are associated with favourable survival after liver transplantation for hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 209-219	5.3	1

518	Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. <i>Hepatology</i> , <b>2021</b> , 73, 1275-1289	11.2	20
517	In Vivo H MR Spectroscopy of Biliary Components of Human Gallbladder at 7T. <i>Journal of Magnetic Resonance Imaging</i> , <b>2021</b> , 53, 98-107	5.6	2
516	Interval cancer after colonoscopy in the Austrian National Screening Programme: influence of physician and patient factors. <i>Gut</i> , <b>2021</b> , 70, 1309-1317	19.2	7
515	Reply to: "Challenges in understanding the consequences of variants in ABCB4 gene". <i>Journal of Hepatology</i> , <b>2021</b> , 74, 244-245	13.4	
514	Systemic inflammation increases across distinct stages of advanced chronic liver disease and correlates with decompensation and mortality. <i>Journal of Hepatology</i> , <b>2021</b> , 74, 819-828	13.4	33
513	Prevalence of anti-Hepatitis E antibodies and impact on disease severity in non-alcoholic fatty liver disease. <i>Hepatology Research</i> , <b>2021</b> , 51, 69-79	5.1	1
512	Placental growth factor levels neither reflect severity of portal hypertension nor portal-hypertensive gastropathy in patients with advanced chronic liver disease. <i>Digestive and Liver Disease</i> , <b>2021</b> , 53, 345-352	3.3	
511	Pathophysiological mechanisms of liver injury in COVID-19. <i>Liver International</i> , <b>2021</b> , 41, 20-32	7.9	99
510	The Association of Histologic and Noninvasive Tests With Adverse Clinical and Patient-Reported Outcomes in Patients With Advanced Fibrosis Due to Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , <b>2021</b> , 160, 1608-1619.e13	13.3	15
509	Prognostic impact of sarcopenia in cirrhotic patients stratified by different severity of portal hypertension. <i>Liver International</i> , <b>2021</b> , 41, 799-809	7.9	8
508	Perceptions on the management of varices and on the use of albumin in patients with cirrhosis among GI specialists in Austria. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 421-431	2.3	2
507	Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2021</b> , 478, 343-353	5.1	52
506	Recent outbreaks of severe hepatitis A virus infections in Vienna. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , <b>2021</b> , 40, 335-344	5.3	2
505	Open-label phase II study evaluating safety and efficacy of the non-steroidal farnesoid X receptor agonist PX-104 in non-alcoholic fatty liver disease. <i>Wiener Klinische Wochenschrift</i> , <b>2021</b> , 133, 441-451	2.3	14
504	Primary Biliary Cholangitis (PBC) <b>2021</b> , 368-376		
503	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome. <i>Annals of Internal Medicine</i> , <b>2021</b> , 174, 139-140	8	1
502	COVID-19 autopsies: Procedure, technical aspects and cause of fatal course. Experiences from a single-center. <i>Pathology Research and Practice</i> , <b>2021</b> , 217, 153305	3.4	12
501	The Non-Steroidal FXR Agonist Cilofexor Improves Portal Hypertension and Reduces Hepatic Fibrosis in a Rat NASH Model. <i>Biomedicines</i> , <b>2021</b> , 9,	4.8	15

500	Absence of Adiponutrin (PNPLA3) and Monoacylglycerol Lipase Synergistically Increases Weight Gain and Aggravates Steatohepatitis in Mice. <i>International Journal of Molecular Sciences</i> , <b>2021</b> , 22,	6.3	1
499	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , <b>2021</b> ,	19.2	5
498	From the origin of NASH to the future of metabolic fatty liver disease. <i>Gut</i> , <b>2021</b> ,	19.2	14
497	The energy sensor AMPK orchestrates metabolic and translational adaptation in expanding T helper cells. <i>FASEB Journal</i> , <b>2021</b> , 35, e21217	0.9	2
496	Role of FXR in Bile Acid and Metabolic Homeostasis in NASH: Pathogenetic Concepts and Therapeutic Opportunities. <i>Seminars in Liver Disease</i> , <b>2021</b> , 41, 461-475	7.3	5
495	24-Norursodeoxycholic acid reshapes immunometabolism in CD8 T cells and alleviates hepatic inflammation. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 1164-1176	13.4	3
494	Hepatocyte-specific deletion of adipose triglyceride lipase (adipose triglyceride lipase/patatin-like phospholipase domain containing 2) ameliorates dietary induced steatohepatitis in mice. <i>Hepatology</i> , <b>2021</b> ,	11.2	7
493	Diet and exercise in NAFLD/NASH: Beyond the obvious. <i>Liver International</i> , <b>2021</b> , 41, 2249-2268	7.9	8
492	The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality. <i>Hepatology</i> , <b>2021</b> , 74, 1533-1545	11.2	7
491	Epidemiological trends of HBV and HDV coinfection among Viennese HIV+ patients. <i>Liver International</i> , <b>2021</b> , 41, 2622-2634	7.9	0
490	Morphometric Analysis of Mast Cells in Tumor Predicts Recurrence of Hepatocellular Carcinoma After Liver Transplantation. <i>Hepatology Communications</i> , <b>2021</b> , 5, 1939-1952	6	0
489	COVID-19 pandemic: Impact on the management of patients with hepatocellular carcinoma at a tertiary care hospital. <i>PLoS ONE</i> , <b>2021</b> , 16, e0256544	3.7	1
488	New risk stratification after colorectal polypectomy reduces burden of surveillance without increasing mortality. <i>United European Gastroenterology Journal</i> , <b>2021</b> , 9, 947-954	5.3	3
487	Spatio-Temporal Multiscale Analysis of Western Diet-Fed Mice Reveals a Translationally Relevant Sequence of Events during NAFLD Progression. <i>Cells</i> , <b>2021</b> , 10,	7.9	1
486	Review article: therapeutic aspects of bile acid signalling in the gut-liver axis. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2021</b> , 54, 1243-1262	6.1	5
485	Downregulation of TGR5 (GPBAR1) in biliary epithelial cells contributes to the pathogenesis of sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2021</b> , 75, 634-646	13.4	11
484	Modern imaging of cholangitis. <i>British Journal of Radiology</i> , <b>2021</b> , 94, 20210417	3.4	1
483	On the Mechanisms of Biliary Flux. <i>Hepatology</i> , <b>2021</b> , 74, 3497-3512	11.2	6

482	Characterization of endogenous bile acid composition in individuals with cold-activated brown adipose tissue. <i>Molecular and Cellular Endocrinology</i> , <b>2021</b> , 536, 111403	4.4	1
481	Accuracy of non-invasive liver stiffness measurement and steatosis quantification in patients with severe and morbid obesity. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2021</b> , 10, 610-622	2.1	1
480	Nuclear receptors in liver fibrosis. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2021</b> , 1867, 166235	6.9	4
479	The Tyrosine Kinase Tec Regulates Effector Th17 Differentiation, Pathogenicity, and Plasticity in T-Cell-Driven Intestinal Inflammation.. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 750466	8.4	0
478	Empfehlungen der ÖGH zur Darmkrebsvorsorge und Nachsorge nach koloskopischer Polypektomie Update 2021. <i>Journal Fuer Gastroenterologische Und Hepatologische Erkrankungen</i> , <b>2021</b> , 19, 105-109	0	1
477	Distinct prognostic value of different portal hypertension-associated features in patients with primary biliary cholangitis. <i>Journal of Gastroenterology</i> , <b>2021</b> , 57, 99	6.9	1
476	Non-invasive monitoring of liver disease regression in patients with advanced chronic liver disease after sustained virologic response to INF-free therapies. <i>Journal of Hepatology</i> , <b>2020</b> , 73, S105	13.4	3
475	Vitamin A levels reflect disease severity and portal hypertension in patients with cirrhosis. <i>Hepatology International</i> , <b>2020</b> , 14, 1093-1103	8.8	1
474	Non-invasive detection of portal hypertension by enhanced liver fibrosis score in patients with different aetiologies of advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 1713-1724	7.9	8
473	Variants in ABCB4 (MDR3) across the spectrum of cholestatic liver diseases in adults. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 651-663	13.4	17
472	Liver Phenotypes of European Adults Heterozygous or Homozygous for Pi*Z Variant of AAT (Pi*MZ vs Pi*ZZ genotype) and Noncarriers. <i>Gastroenterology</i> , <b>2020</b> , 159, 534-548.e11	13.3	29
471	Risk for development of inflammatory bowel disease under inhibition of interleukin 17: A systematic review and meta-analysis. <i>PLoS ONE</i> , <b>2020</b> , 15, e0233781	3.7	15
470	Absence of Bsep/Abcb11 attenuates MCD diet-induced hepatic steatosis but aggravates inflammation in mice. <i>Liver International</i> , <b>2020</b> , 40, 1366-1377	7.9	7
469	Altered Microbiota Diversity and Bile Acid Signaling in Cirrhotic and Noncirrhotic NASH-HCC. <i>Clinical and Translational Gastroenterology</i> , <b>2020</b> , 11, e00131	4.2	26
468	Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 26-39	13.4	137
467	Plasma Levels of the Bioactive Sphingolipid Metabolite S1P in Adult Cystic Fibrosis Patients: Potential Target for Immunonutrition?. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	5
466	Lysosomal acid lipase is the major acid retinyl ester hydrolase in cultured human hepatic stellate cells but not essential for retinyl ester degradation. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2020</b> , 1865, 158730	5	5
465	FXR-dependent Rubicon induction impairs autophagy in models of human cholestasis. <i>Journal of Hepatology</i> , <b>2020</b> , 72, 1122-1131	13.4	22

464	The impact of ABO blood type on the prevalence of portal vein thrombosis in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 1415-1426	7.9	10
463	Metabolic regulation of hepatic PNPLA3 expression and severity of liver fibrosis in patients with NASH. <i>Liver International</i> , <b>2020</b> , 40, 1098-1110	7.9	11
462	Epidemiological trends in HCV transmission and prevalence in the Viennese HIV+ population. <i>Liver International</i> , <b>2020</b> , 40, 787-796	7.9	6
461	Anemia and iron deficiency in compensated and decompensated cirrhosis: Prevalence and impact on clinical outcomes. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2020</b> , 35, 1619-1627	4	3
460	Novel reliability criteria for controlled attenuation parameter assessments for non-invasive evaluation of hepatic steatosis. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 321-331	5.3	13
459	Pathophysiologic Basis for Alternative Therapies for Cholestasis <b>2020</b> , 364-377		1
458	E2F-Family Members Engage the PIDDosome to Limit Hepatocyte Ploidy in Liver Development and Regeneration. <i>Developmental Cell</i> , <b>2020</b> , 52, 335-349.e7	10.2	21
457	Bile Acids as Signaling Molecules <b>2020</b> , 299-312		2
456	The Role of Metabolic Lipases in the Pathogenesis and Management of Liver Disease. <i>Hepatology</i> , <b>2020</b> , 72, 1117-1126	11.2	14
455	Reply. <i>Hepatology</i> , <b>2020</b> , 72, 1498-1499	11.2	
454	NCOR1 Orchestrates Transcriptional Landscapes and Effector Functions of CD4 T Cells. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 579	8.4	5
453	Impact of osteopontin on the development of non-alcoholic liver disease and related hepatocellular carcinoma. <i>Liver International</i> , <b>2020</b> , 40, 1620-1633	7.9	7
452	S0984 Long-Term Efficacy and Safety of Obeticholic Acid in Patients With Primary Biliary Cholangitis: A Demographic Subgroup Analysis of 5-Year Results From the POISE Trial. <i>American Journal of Gastroenterology</i> , <b>2020</b> , 115, S501-S502	0.7	
451	Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy. <i>Journal of Visualized Experiments</i> , <b>2020</b> ,	1.6	23
450	Bile Acids and Bilirubin in Liver Immunology <b>2020</b> , 103-124		
449	Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis. <i>Hepatology</i> , <b>2020</b> , 71, 1750-1765	11.2	10
448	Optical control of the nuclear bile acid receptor FXR with a photohormone. <i>Chemical Science</i> , <b>2020</b> , 11, 429-434	9.4	14
447	Portal hypertensive gastropathy is associated with iron deficiency anemia. <i>Wiener Klinische Wochenschrift</i> , <b>2020</b> , 132, 1-11	2.3	7



446	Hepatic Steatosis in Lean Patients: Risk Factors and Impact on Mortality. <i>Digestive Diseases and Sciences</i> , <b>2020</b> , 65, 2712-2718	4	1
445	Methylation signatures in peripheral blood are associated with marked age acceleration and disease progression in patients with primary sclerosing cholangitis. <i>JHEP Reports</i> , <b>2020</b> , 2, 100060	10.3	6
444	The von Willebrand Factor antigen to platelet ratio (VITRO) score predicts hepatic decompensation and mortality in cirrhosis. <i>Journal of Gastroenterology</i> , <b>2020</b> , 55, 533-542	6.9	9
443	Impact of HSD17B13 rs72613567 genotype on hepatic decompensation and mortality in patients with portal hypertension. <i>Liver International</i> , <b>2020</b> , 40, 393-404	7.9	9
442	Metabolic effects of a prolonged, very-high-dose dietary fructose challenge in healthy subjects. <i>American Journal of Clinical Nutrition</i> , <b>2020</b> , 111, 369-377	7	10
441	The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation. <i>Hepatology</i> , <b>2020</b> , 72, 584-594	11.2	10
440	Non-invasive diagnosis of cirrhosis and long-term disease monitoring by transient elastography in patients with Wilson disease. <i>Liver International</i> , <b>2020</b> , 40, 894-904	7.9	8
439	Vascular Complications in Patients with Hepatocellular Carcinoma Treated with Sorafenib. <i>Cancers</i> , <b>2020</b> , 12,	6.6	3
438	PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	4
437	Pulmonary Arterial Thrombosis in COVID-19 With Fatal Outcome : Results From a Prospective, Single-Center, Clinicopathologic Case Series. <i>Annals of Internal Medicine</i> , <b>2020</b> , 173, 350-361	8	434
436	Pulmonary arterial thrombosis as an important complication of COVID-19 pulmonary disease: letter to the editor. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2020</b> , 477, 467-468	5.1	7
435	Comparison of the diagnostic quality of aspiration and core-biopsy needles for transjugular liver biopsy. <i>Digestive and Liver Disease</i> , <b>2020</b> , 52, 1473-1479	3.3	2
434	Soluble guanylyl cyclase stimulation and phosphodiesterase-5 inhibition improve portal hypertension and reduce liver fibrosis in bile duct-ligated rats. <i>United European Gastroenterology Journal</i> , <b>2020</b> , 8, 1174-1185	5.3	6
433	EASL Recognition Award Recipient 2020: Prof. James L. Boyer. <i>Journal of Hepatology</i> , <b>2020</b> , 73, 487-489	13.4	
432	MRI-defined sarcopenia predicts mortality in patients with chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 2797-2807	7.9	11
431	Clinical Course of Porto-Sinusoidal Vascular Disease Is Distinct From Idiopathic Noncirrhotic Portal Hypertension. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> ,	6.9	4
430	Effects of Vedolizumab in Patients With Primary Sclerosing Cholangitis and Inflammatory Bowel Diseases. <i>Clinical Gastroenterology and Hepatology</i> , <b>2020</b> , 18, 179-187.e6	6.9	24
429	Impact of adenoma detection rate on detection of advanced adenomas and endoscopic adverse events in a study of over 200,000 screening colonoscopies. <i>Gastrointestinal Endoscopy</i> , <b>2020</b> , 91, 135-141	5.2	10



428	Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. <i>Hepatology</i> , <b>2020</b> , 71, 1023-1036	11.2	67
427	Prevalence of and risk factors for anaemia in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2020</b> , 40, 194-204	7.9	19
426	Patterns and prevalence of dyslipidemia in patients with different etiologies of chronic liver disease. <i>Wiener Klinische Wochenschrift</i> , <b>2019</b> , 131, 395-403	2.3	5
425	Antifibrotic effects of hypocalcemic vitamin D analogs in murine and human hepatic stellate cells and in the CCl mouse model. <i>Laboratory Investigation</i> , <b>2019</b> , 99, 1906-1917	5.9	8
424	The challenges of primary biliary cholangitis: What is new and what needs to be done. <i>Journal of Autoimmunity</i> , <b>2019</b> , 105, 102328	15.5	45
423	The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. <i>Hepatology</i> , <b>2019</b> , 70, 788-801	11.2	101
422	Liver Injury and Failure in Critical Illness. <i>Hepatology</i> , <b>2019</b> , 70, 2204-2215	11.2	34
421	Performance of Controlled Attenuation Parameter in Patients with Advanced Chronic Liver Disease and Portal Hypertension. <i>Digestive Diseases and Sciences</i> , <b>2019</b> , 64, 3642-3651	4	5
420	Obeticholic acid may increase the risk of gallstone formation in susceptible patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 986-991	13.4	28
419	C-reactive protein is an independent predictor for hepatocellular carcinoma recurrence after liver transplantation. <i>PLoS ONE</i> , <b>2019</b> , 14, e0216677	3.7	13
418	The zinc-finger transcription factor MAZR regulates iNKT cell subset differentiation. <i>Cellular and Molecular Life Sciences</i> , <b>2019</b> , 76, 4391-4404	10.3	3
417	Impact of farnesoid X receptor single nucleotide polymorphisms on hepatic decompensation and mortality in cirrhotic patients with portal hypertension. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2019</b> , 34, 2164-2172	4	8
416	Prevalence and Predictors of Hepatic Steatosis in Patients with HIV/HCV Coinfection and the Impact of HCV Eradication. <i>AIDS Patient Care and STDs</i> , <b>2019</b> , 33, 197-206	5.8	9
415	Management of patients with chronic hepatitis C failing repeated courses of interferon-free direct acting antiviral combination therapy. <i>GastroHep</i> , <b>2019</b> , 1, 76-83	1	3
414	Reduced Patient-Reported Outcome Scores Associate With Level of Fibrosis in Patients With Nonalcoholic Steatohepatitis. <i>Clinical Gastroenterology and Hepatology</i> , <b>2019</b> , 17, 2552-2560.e10	6.9	33
413	Lack of monoacylglycerol lipase prevents hepatic steatosis by favoring lipid storage in adipose tissue and intestinal malabsorption. <i>Journal of Lipid Research</i> , <b>2019</b> , 60, 1284-1292	6.3	14
412	THU-023-Monoacylglycerol lipase inhibition protects from hepatic inflammation and fibrosis in mouse models of sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2019</b> , 70, e170	13.4	3
411	Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 445-453	18.8	73

410	High efficacy of interferon-free therapy for acute hepatitis C in HIV-positive patients. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 507-516	5.3	14
409	Transjugular aspiration liver biopsy performed by hepatologists trained in HVPG measurements is safe and provides important diagnostic information. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 1144-1151	3.3	14
408	Resection rates and safety profile of cold vs. hot snare polypectomy in polyps sized 5-10 mm and 11-20 mm. <i>Digestive and Liver Disease</i> , <b>2019</b> , 51, 536-541	3.3	7
407	Ascitic fluid polymorphic nuclear cell count impacts on outcome of cirrhotic patients with ascites. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 651-661	5.3	2
406	HSD17B13 truncated variant is associated with a mild hepatic phenotype in Wilson's Disease. <i>JHEP Reports</i> , <b>2019</b> , 1, 2-8	10.3	11
405	Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2019</b> , 49, 1323-1333	6.1	61
404	Heterozygous carriage of the alpha1-antitrypsin Pi*Z variant increases the risk to develop liver cirrhosis. <i>Gut</i> , <b>2019</b> , 68, 1099-1107	19.2	62
403	Lactate Improves Prediction of Short-Term Mortality in Critically Ill Patients With Cirrhosis: A Multinational Study. <i>Hepatology</i> , <b>2019</b> , 69, 258-269	11.2	44
402	The Efficacy of MRI in the diagnostic workup of cystic fibrosis-associated liver disease: A clinical observational cohort study. <i>European Radiology</i> , <b>2019</b> , 29, 1048-1058	8	12
401	Controlled attenuation parameter does not predict hepatic decompensation in patients with advanced chronic liver disease. <i>Liver International</i> , <b>2019</b> , 39, 127-135	7.9	32
400	The value of different CT-based methods for diagnosing low muscle mass and predicting mortality in patients with cirrhosis. <i>Liver International</i> , <b>2019</b> , 39, 2374-2385	7.9	24
399	Guideline-conform statin use reduces overall mortality in patients with compensated liver disease. <i>Scientific Reports</i> , <b>2019</b> , 9, 11674	4.9	5
398	Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial. <i>The Lancet Gastroenterology and Hepatology</i> , <b>2019</b> , 4, 781-793	18.8	29
397	Short- and long-term effects of transarterial chemoembolization on portal hypertension in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 850-858	5.3	8
396	Liver Fibrosis and Metabolic Alterations in Adults With alpha-1-antitrypsin Deficiency Caused by the Pi*ZZ Mutation. <i>Gastroenterology</i> , <b>2019</b> , 157, 705-719.e18	13.3	50
395	Noninvasive Tests Accurately Identify Advanced Fibrosis due to NASH: Baseline Data From the STELLAR Trials. <i>Hepatology</i> , <b>2019</b> , 70, 1521-1530	11.2	113
394	I148M Variant Impairs Liver X Receptor Signaling and Cholesterol Homeostasis in Human Hepatic Stellate Cells. <i>Hepatology Communications</i> , <b>2019</b> , 3, 1191-1204	6	18
393	Evaluation and comparison of six noninvasive tests for prediction of significant or advanced fibrosis in nonalcoholic fatty liver disease. <i>United European Gastroenterology Journal</i> , <b>2019</b> , 7, 1113-1123	5.3	33

392	The impact of hepatic steatosis on portal hypertension. <i>PLoS ONE</i> , <b>2019</b> , 14, e0224506	3.7	5
391	Gut-liver axis signaling in portal hypertension. <i>World Journal of Gastroenterology</i> , <b>2019</b> , 25, 5897-5917	5.6	35
390	Detection of Various Microplastics in Human Stool: A Prospective Case Series. <i>Annals of Internal Medicine</i> , <b>2019</b> , 171, 453-457	8	357
389	Type I Interferon Signaling Disrupts the Hepatic Urea Cycle and Alters Systemic Metabolism to Suppress T Cell Function. <i>Immunity</i> , <b>2019</b> , 51, 1074-1087.e9	32.3	41
388	Towards a nationwide implementation of a standardized nutrition and dietetics terminology in clinical practice: a pre-implementation focus group study including a pretest and using the consolidated framework for implementation research. <i>BMC Health Services Research</i> , <b>2019</b> , 19, 920	2.9	5
387	Fine-Tuning of Sirtuin 1 Expression Is Essential to Protect the Liver From Cholestatic Liver Disease. <i>Hepatology</i> , <b>2019</b> , 69, 699-716	11.2	21
386	Association of Platelet Count and Mean Platelet Volume with Overall Survival in Patients with Cirrhosis and Unresectable Hepatocellular Carcinoma. <i>Liver Cancer</i> , <b>2019</b> , 8, 203-217	9.1	31
385	High seroprevalence of anti-Hepatitis E antibodies in Austrian patients with autoimmune hepatitis. <i>Liver International</i> , <b>2019</b> , 39, 640-645	7.9	9
384	Evaluation of adenomas per colonoscopy and adenomas per positive participant as new quality parameters in screening colonoscopy. <i>Gastrointestinal Endoscopy</i> , <b>2019</b> , 89, 496-502	5.2	13
383	Inhibition of monoacylglycerol lipase, an anti-inflammatory and antifibrogenic strategy in the liver. <i>Gut</i> , <b>2019</b> , 68, 522-532	19.2	39
382	Dysbalanced sex hormone status is an independent predictor of decompensation and mortality in patients with liver cirrhosis. <i>Hepatology Research</i> , <b>2019</b> , 49, 201-211	5.1	8
381	Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study. <i>Liver International</i> , <b>2019</b> , 39, 290-298	7.9	20
380	Deviations of the immune cell landscape between healthy liver and hepatocellular carcinoma. <i>Scientific Reports</i> , <b>2018</b> , 8, 6220	4.9	99
379	Na <sup>+</sup> -taurocholate cotransporting polypeptide inhibition has hepatoprotective effects in cholestasis in mice. <i>Hepatology</i> , <b>2018</b> , 68, 1057-1069	11.2	32
378	Colesevelam attenuates cholestatic liver and bile duct injury in mice by modulating composition, signalling and excretion of faecal bile acids. <i>Gut</i> , <b>2018</b> , 67, 1683-1691	19.2	35
377	[C]acetate PET as a tool for diagnosis of liver steatosis. <i>Abdominal Radiology</i> , <b>2018</b> , 43, 2963-2969	3	2
376	Erectile dysfunction in cirrhosis is impacted by liver dysfunction, portal hypertension, diabetes and arterial hypertension. <i>Liver International</i> , <b>2018</b> , 38, 1427-1436	7.9	16
375	Recent Insights into the Pathogenesis of Nonalcoholic Fatty Liver Disease. <i>Annual Review of Pathology: Mechanisms of Disease</i> , <b>2018</b> , 13, 321-350	34	234

374	Acid-base status and its clinical implications in critically ill patients with cirrhosis, acute-on-chronic liver failure and without liver disease. <i>Annals of Intensive Care</i> , <b>2018</b> , 8, 48	8.9	16
373	Lysyl oxidase-like protein 2 (LOXL2) modulates barrier function in cholangiocytes in cholestasis. <i>Journal of Hepatology</i> , <b>2018</b> , 69, 368-377	13.4	16
372	Chromosomal instability in HCC: a key function for checkpoint kinase 2. <i>Gut</i> , <b>2018</b> , 67, 204-205	19.2	1
371	Management of portal hypertension before and after liver transplantation. <i>Liver Transplantation</i> , <b>2018</b> , 24, 112-121	4.5	12
370	ePTFE-TIPS vs repetitive LVP plus albumin for the treatment of refractory ascites in patients with cirrhosis. <i>Liver International</i> , <b>2018</b> , 38, 1036-1044	7.9	20
369	Surveillance colonoscopy in Austria: Are we following the guidelines?. <i>Endoscopy</i> , <b>2018</b> , 50, 119-127	3.4	8
368	Significant Liver-Related Morbidity After Bariatric Surgery and Its Reversal-a Case Series. <i>Obesity Surgery</i> , <b>2018</b> , 28, 812-819	3.7	42
367	Ursodeoxycholic acid: Effects on hepatic unfolded protein response, apoptosis and oxidative stress in morbidly obese patients. <i>Liver International</i> , <b>2018</b> , 38, 523-531	7.9	18
366	The soluble guanylate cyclase stimulator riociguat reduces fibrogenesis and portal pressure in cirrhotic rats. <i>Scientific Reports</i> , <b>2018</b> , 8, 9372	4.9	24
365	Invasive Hemodynamic Characterization of the Portal-hypertensive Syndrome in Cirrhotic Rats. <i>Journal of Visualized Experiments</i> , <b>2018</b> ,	1.6	3
364	NorUDCA promotes degradation of $\alpha$ -antitrypsin mutant Z protein by inducing autophagy through AMPK/ULK1 pathway. <i>PLoS ONE</i> , <b>2018</b> , 13, e0200897	3.7	18
363	Nuclear Receptor Regulation of Aquaglyceroporins in Metabolic Organs. <i>International Journal of Molecular Sciences</i> , <b>2018</b> , 19,	6.3	7
362	Waitlist mortality and post-transplant survival in patients with cholestatic liver disease - Impact of changes in allocation policy. <i>Hpb</i> , <b>2018</b> , 20, 916-924	3.8	7
361	miR-30a Remodels Subcutaneous Adipose Tissue Inflammation to Improve Insulin Sensitivity in Obesity. <i>Diabetes</i> , <b>2018</b> , 67, 2541-2553	0.9	44
360	Noninvasive Monitoring of Liver Disease Regression after Hepatitis C Eradication Using Gadoteric Acid-Enhanced MRI. <i>Contrast Media and Molecular Imaging</i> , <b>2018</b> , 2018, 8489709	3.2	6
359	Liver disease in adults with $\alpha$ -antitrypsin deficiency. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 710-718	5.3	16
358	Transjugular intrahepatic portosystemic shunts (TIPS) for the prevention of variceal re-bleeding - A two decades experience. <i>PLoS ONE</i> , <b>2018</b> , 13, e0189414	3.7	18
357	Genetic Regulation of Plasma Lipid Species and Their Association with Metabolic Phenotypes. <i>Cell Systems</i> , <b>2018</b> , 6, 709-721.e6	10.6	31

356	Anticoagulation in non-malignant portal vein thrombosis is safe and improves hepatic function. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 446-455	2.3	26
355	Impact of glutathione peroxidase 4 on cell proliferation, angiogenesis and cytokine production in hepatocellular carcinoma. <i>Oncotarget</i> , <b>2018</b> , 9, 10054-10068	3.3	14
354	Long-term follow-up of ribavirin-free DAA-based treatment in HCV recurrence after orthotopic liver transplantation. <i>Liver International</i> , <b>2018</b> , 38, 1188-1197	7.9	5
353	Follow-up of sustained virological responders with hepatitis C and advanced liver disease after interferon/ribavirin-free treatment. <i>Liver International</i> , <b>2018</b> , 38, 1028-1035	7.9	40
352	Non-invasive liver fibrosis assessment and HCV treatment initiation within a systematic screening program in HIV/HCV coinfecting patients. <i>Wiener Klinische Wochenschrift</i> , <b>2018</b> , 130, 105-114	2.3	11
351	Hepatocyte specific expression of an oncogenic variant of $\beta$ -catenin results in lethal metabolic dysfunction in mice. <i>Oncotarget</i> , <b>2018</b> , 9, 11243-11257	3.3	3
350	Point Shear Wave Elastography for Non-invasive Assessment of Liver Fibrosis in Patients with Viral Hepatitis. <i>Ultrasound in Medicine and Biology</i> , <b>2018</b> , 44, 2578-2586	3.5	6
349	Impact of nutritional status on pulmonary function after lung transplantation for cystic fibrosis. <i>United European Gastroenterology Journal</i> , <b>2018</b> , 6, 1049-1055	5.3	7
348	Thyroid hormone receptor $\alpha$ stimulates to increase biliary phosphatidylcholine excretion in mice. <i>Journal of Lipid Research</i> , <b>2018</b> , 59, 1610-1619	6.3	8
347	A Microbial Signature of Psychological Distress in Irritable Bowel Syndrome. <i>Psychosomatic Medicine</i> , <b>2018</b> , 80, 698-709	3.7	41
346	Prevalence of Helicobacter pylori and its CagA subtypes in gastric cancer and duodenal ulcer at an Austrian tertiary referral center over 25 years. <i>PLoS ONE</i> , <b>2018</b> , 13, e0197695	3.7	6
345	Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2017</b> , 32, 184-190	4	12
344	The PNPLA3 I148M variant modulates the fibrogenic phenotype of human hepatic stellate cells. <i>Hepatology</i> , <b>2017</b> , 65, 1875-1890	11.2	126
343	Fibrosis evaluation by transient elastography in alcoholic liver disease: Is the histological scoring system impacting cutoff values?. <i>Hepatology</i> , <b>2017</b> , 65, 1758-1761	11.2	4
342	Renal replacement therapy in critically ill liver cirrhotic patients-outcome and clinical implications. <i>Liver International</i> , <b>2017</b> , 37, 843-850	7.9	31
341	Patient Age, Sex, and Inflammatory Bowel Disease Phenotype Associate With Course of Primary Sclerosing Cholangitis. <i>Gastroenterology</i> , <b>2017</b> , 152, 1975-1984.e8	13.3	219
340	NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 110-119	13.4	30
339	Nor-Ursodeoxycholic Acid as a Novel Therapeutic Approach for Cholestatic and Metabolic Liver Diseases. <i>Digestive Diseases</i> , <b>2017</b> , 35, 288-292	3.2	22

338	Impact of higher-order heme degradation products on hepatic function and hemodynamics. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 272-281	13.4	15
337	Targeting the gut-liver axis in liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1084-1103	13.4	199
336	Circulating bile acids predict outcome in critically ill patients. <i>Annals of Intensive Care</i> , <b>2017</b> , 7, 48	8.9	28
335	Photodynamic therapy with polyhematoporphyrin for malignant biliary obstruction: A nationwide retrospective study of 150 consecutive applications. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 104-110	5.3	16
334	norUrsodeoxycholic acid improves cholestasis in primary sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 549-558	13.4	138
333	Non-selective beta-blocker treatment does not impact on kidney function in cirrhotic patients with varices. <i>Scandinavian Journal of Gastroenterology</i> , <b>2017</b> , 52, 1008-1015	2.4	6
332	Ultra-high-field magnetic resonance spectroscopy in non-alcoholic fatty liver disease: Novel mechanistic and diagnostic insights of energy metabolism in non-alcoholic steatohepatitis and advanced fibrosis. <i>Liver International</i> , <b>2017</b> , 37, 1544-1553	7.9	23
331	Therapeutic Mechanisms of Bile Acids and Nor-Ursodeoxycholic Acid in Non-Alcoholic Fatty Liver Disease. <i>Digestive Diseases</i> , <b>2017</b> , 35, 282-287	3.2	20
330	Use of inhibitors of the renin-angiotensin system is associated with longer survival in patients with hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 987-996	5.3	33
329	Novel treatments targeting metabolic and signaling mechanisms in primary biliary cholangitis. <i>Clinical Liver Disease</i> , <b>2017</b> , 9, 43-47	2.2	5
328	ABC Transporters Involved in Cholestasis. <i>Methods and Principles in Medicinal Chemistry</i> , <b>2017</b> , 119-166	0.4	
327	Metabolic preconditioning protects BSEP/ABCB11 mice against cholestatic liver injury. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 95-101	13.4	37
326	Serum bile acids in patients with hepatopulmonary syndrome. <i>Zeitschrift Fur Gastroenterologie</i> , <b>2017</b> , 55, 361-367	1.6	5
325	New therapeutic concepts in bile acid transport and signaling for management of cholestasis. <i>Hepatology</i> , <b>2017</b> , 65, 1393-1404	11.2	114
324	The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. <i>Journal of Hepatology</i> , <b>2017</b> , 66, 724-733	13.4	87
323	Austrian consensus guidelines on the management and treatment of portal hypertension (BillrothIII). <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 135-158	2.3	76
322	FXR controls CHOP expression in steatohepatitis. <i>FEBS Letters</i> , <b>2017</b> , 591, 3360-3368	3.8	10
321	Single-sex infection with female <i>Schistosoma mansoni</i> cercariae mitigates hepatic fibrosis after secondary infection. <i>PLoS Neglected Tropical Diseases</i> , <b>2017</b> , 11, e0005595	4.8	10



320	PNPLA3 expression and its impact on the liver: current perspectives. <i>Hepatic Medicine: Evidence and Research</i> , <b>2017</b> , 9, 55-66	3.4	42
319	Oxidative stress mediates an increased formation of vascular endothelial growth factor in human hepatocarcinoma cells exposed to erlotinib. <i>Oncotarget</i> , <b>2017</b> , 8, 57109-57120	3.3	4
318	Cystic Fibrosis-related Liver Disease: Research Challenges and Future Perspectives. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2017</b> , 65, 443-448	2.8	53
317	The post-transplant course of patients undergoing liver transplantation for nonalcoholic steatohepatitis versus cryptogenic cirrhosis: a retrospective case-control study. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2017</b> , 29, 309-316	2.2	10
316	Molecular Mechanism of Taurocholate Transport by the Bile Salt Export Pump, an ABC Transporter Associated with Intrahepatic Cholestasis. <i>Molecular Pharmacology</i> , <b>2017</b> , 92, 401-413	4.3	8
315	Re-bleeding rates and survival after early transjugular intrahepatic portosystemic shunt (TIPS) in clinical practice. <i>Digestive and Liver Disease</i> , <b>2017</b> , 49, 1360-1367	3.3	15
314	AQP3 is regulated by PPAR $\alpha$ and JNK in hepatic stellate cells carrying PNPLA3 I148M. <i>Scientific Reports</i> , <b>2017</b> , 7, 14661	4.9	15
313	Effects of Portal Hypertension on Gadoteric Acid-Enhanced Liver Magnetic Resonance: Diagnostic and Prognostic Implications. <i>Investigative Radiology</i> , <b>2017</b> , 52, 462-469	10.1	11
312	Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna. <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 517-526	2.3	8
311	Acid-base disorders in liver disease. <i>Journal of Hepatology</i> , <b>2017</b> , 67, 1062-1073	13.4	48
310	Adiponectin regulates AQP3 via PPAR $\beta$ in human hepatic stellate cells. <i>Biochemical and Biophysical Research Communications</i> , <b>2017</b> , 490, 51-54	3.4	14
309	Vitamin D Loading Is Superior to Conventional Supplementation After Weight Loss Surgery in Vitamin D-Deficient Morbidly Obese Patients: a Double-Blind Randomized Placebo-Controlled Trial. <i>Obesity Surgery</i> , <b>2017</b> , 27, 1196-1207	3.7	21
308	Hepatic gadoteric acid uptake as a measure of diffuse liver disease: Where are we?. <i>Journal of Magnetic Resonance Imaging</i> , <b>2017</b> , 45, 646-659	5.6	35
307	Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome. <i>Journal of Trace Elements in Medicine and Biology</i> , <b>2017</b> , 39, 100-107	10.7	21
306	Serum bile acids as marker for acute decompensation and acute-on-chronic liver failure in patients with non-cholestatic cirrhosis. <i>Liver International</i> , <b>2017</b> , 37, 224-231	7.9	29
305	Bile acids and nonalcoholic fatty liver disease: Molecular insights and therapeutic perspectives. <i>Hepatology</i> , <b>2017</b> , 65, 350-362	11.2	301
304	Low 25-OH-vitamin D levels reflect hepatic dysfunction and are associated with mortality in patients with liver cirrhosis. <i>Wiener Klinische Wochenschrift</i> , <b>2017</b> , 129, 8-15	2.3	28
303	The role of TIPS in the management of liver transplant candidates. <i>United European Gastroenterology Journal</i> , <b>2017</b> , 5, 1100-1107	5.3	11



302	The non-invasive serum biomarker soluble Axl accurately detects advanced liver fibrosis and cirrhosis. <i>Cell Death and Disease</i> , <b>2017</b> , 8, e3135	9.8	22
301	The impact of thyroid hormones on patients with hepatocellular carcinoma. <i>PLoS ONE</i> , <b>2017</b> , 12, e0181838	3.7	17
300	Ursodeoxycholic acid prevents ventricular conduction slowing and arrhythmia by restoring T-type calcium current in fetuses during cholestasis. <i>PLoS ONE</i> , <b>2017</b> , 12, e0183167	3.7	7
299	Soluble Axl is an accurate biomarker of cirrhosis and hepatocellular carcinoma development: results from a large scale multicenter analysis. <i>Oncotarget</i> , <b>2017</b> , 8, 46234-46248	3.3	32
298	Difficult case of Cronkhite-Canada syndrome with small intestinal bacterial overgrowth, Clostridium difficile infection and polymyalgia rheumatica. <i>BMJ Case Reports</i> , <b>2016</b> , 2016,	0.9	
297	Trends in quality of screening colonoscopy in Austria. <i>Endoscopy</i> , <b>2016</b> , 48, 1102-1109	3.4	17
296	A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis. <i>New England Journal of Medicine</i> , <b>2016</b> , 375, 631-43	59.2	574
295	Liver Capsule: FXR agonists against liver disease. <i>Hepatology</i> , <b>2016</b> , 64, 1773	11.2	11
294	Cancer and liver cirrhosis: implications on prognosis and management. <i>ESMO Open</i> , <b>2016</b> , 1, e000042	6	124
293	Risk factors cannot explain the higher prevalence rates of precancerous colorectal lesions in men. <i>British Journal of Cancer</i> , <b>2016</b> , 115, 1421-1429	8.7	15
292	Treatment intensification with boceprevir in HIV-positive patients with acute HCV-genotype 1 infection at high risk for treatment failure. <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 414-20	2.3	1
291	Endoscopic versus surgical management of biliary complications - Outcome analysis after 1188 orthotopic liver transplantations. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1323-1329	3.3	5
290	Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 856-858	13.4	157
289	Influence of 24-Nor-Ursodeoxycholic Acid on Hepatic Disposition of [(18)F]Ciprofloxacin, a Positron Emission Tomography Study in Mice. <i>Journal of Pharmaceutical Sciences</i> , <b>2016</b> , 105, 106-12	3.9	4
288	Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2016</b> , 64, 674-81	13.4	99
287	A pilot study of confocal laser endomicroscopy for diagnosing gastrointestinal mucosa-associated lymphoid tissue (MALT) lymphoma. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2016</b> , 30, 2879-85	5.2	5
286	Farnesoid X Receptor Agonists and Other Bile Acid Signaling Strategies for Treatment of Liver Disease. <i>Digestive Diseases</i> , <b>2016</b> , 34, 580-8	3.2	30
285	Assessment of Orthotopic Liver Transplant Graft Survival on Gadoteric Acid-Enhanced Magnetic Resonance Imaging Using Qualitative and Quantitative Parameters. <i>Investigative Radiology</i> , <b>2016</b> , 51, 728-734	10.1	17

284	The Effect of Roux-en-Y vs. Omega-Loop Gastric Bypass on Liver, Metabolic Parameters, and Weight Loss. <i>Obesity Surgery</i> , <b>2016</b> , 26, 2204-2212	3.7	36
283	Prevalence of Liver Fibrosis and its Association with Non-invasive Fibrosis and Metabolic Markers in Morbidly Obese Patients with Vitamin D Deficiency. <i>Obesity Surgery</i> , <b>2016</b> , 26, 2425-32	3.7	34
282	Nuclear Receptor Modulation for the Treatment of Nonalcoholic Fatty Liver Disease. <i>Seminars in Liver Disease</i> , <b>2016</b> , 36, 69-86	7.3	67
281	Simvastatin Efficiently Lowers Small LDL-IgG Immune Complex Levels: A Therapeutic Quality beyond the Lipid-Lowering Effect. <i>PLoS ONE</i> , <b>2016</b> , 11, e0148210	3.7	14
280	Hepatocyte specific expression of an oncogenic variant of Eatenin results in cholestatic liver disease. <i>Oncotarget</i> , <b>2016</b> , 7, 86985-86998	3.3	10
279	Role of interleukin-1 and its antagonism of hepatic stellate cell proliferation and liver fibrosis in the Abcb4(-/-) mouse model. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 401-10	3.4	20
278	Recent advances in understanding and managing cholestasis. <i>F1000Research</i> , <b>2016</b> , 5,	3.6	35
277	Biosensor for Hepatocellular Injury Corresponds to Experimental Scoring of Hepatosplenic Schistosomiasis in Mice. <i>BioMed Research International</i> , <b>2016</b> , 2016, 1567254	3	6
276	Interferon-free treatment with sofosbuvir/daclatasvir achieves sustained virologic response in 100% of HIV/hepatitis C virus-coinfected patients with advanced liver disease. <i>Aids</i> , <b>2016</b> , 30, 1039-47	3.5	32
275	Coagulation parameters and major bleeding in critically ill patients with cirrhosis. <i>Hepatology</i> , <b>2016</b> , 64, 556-68	11.2	94
274	The trigger matters - outcome of hepatorenal syndrome vs. specifically triggered acute kidney injury in cirrhotic patients with ascites. <i>Liver International</i> , <b>2016</b> , 36, 1649-1656	7.9	6
273	DAA-based antiviral treatment of patients with chronic hepatitis C in the pre- and postkidney transplantation setting. <i>Transplant International</i> , <b>2016</b> , 29, 999-1007	3	67
272	Surrogate endpoints for clinical trials in primary sclerosing cholangitis: Review and results from an International PSC Study Group consensus process. <i>Hepatology</i> , <b>2016</b> , 63, 1357-67	11.2	94
271	Outcome and features of acute kidney injury complicating hypoxic hepatitis at the medical intensive care unit. <i>Annals of Intensive Care</i> , <b>2016</b> , 6, 61	8.9	17
270	Low levels of IgM antibodies recognizing oxidation-specific epitopes are associated with human non-alcoholic fatty liver disease. <i>BMC Medicine</i> , <b>2016</b> , 14, 107	11.4	15
269	Interferon-free regimens improve health-related quality of life and fatigue in HIV/HCV-coinfected patients with advanced liver disease: A retrospective study. <i>Medicine (United States)</i> , <b>2016</b> , 95, e4061	1.8	15
268	Autophagy induced by exogenous bile acids is therapeutic in a model of H1-AT deficiency liver disease. <i>American Journal of Physiology - Renal Physiology</i> , <b>2016</b> , 311, G156-65	5.1	19
267	Sustained virologic response to interferon-free therapies ameliorates HCV-induced portal hypertension. <i>Journal of Hepatology</i> , <b>2016</b> , 65, 692-699	13.4	190

266	Reply. <i>Hepatology</i> , <b>2016</b> , 63, 346-7	11.2	1
265	Expert consensus document: Cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2016</b> , 13, 261-80	24.2	618
264	A retrospective study on the safety, diagnostic yield, and therapeutic effects of endoscopic unroofing for small gastric subepithelial tumors. <i>Gastrointestinal Endoscopy</i> , <b>2016</b> , 84, 924-929	5.2	2
263	Indications for liver transplantation in adults : Recommendations of the Austrian Society for Gastroenterology and Hepatology (ÖGH) in cooperation with the Austrian Society for Transplantation, Transfusion and Genetics (ATX). <i>Wiener Klinische Wochenschrift</i> , <b>2016</b> , 128, 679-690	2.3	26
262	von Willebrand factor antigen (vWF-Ag): A non-invasive predictor of treatment response and serious adverse events in HCV patients with interferon triple therapy. <i>Digestive and Liver Disease</i> , <b>2016</b> , 48, 1194-9	3.3	1
261	Immunotherapy With the PreS-based Grass Pollen Allergy Vaccine BM32 Induces Antibody Responses Protecting Against Hepatitis B Infection. <i>EBioMedicine</i> , <b>2016</b> , 11, 58-67	8.8	40
260	Bile acids in regulation of inflammation and immunity: friend or foe?. <i>Clinical and Experimental Rheumatology</i> , <b>2016</b> , 34, 25-31	2.2	45
259	Endoscopists with low adenoma detection rates benefit from high-definition endoscopy. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2015</b> , 29, 466-73	5.2	17
258	Phosphatidylcholine contributes to in vivo (31)P MRS signal from the human liver. <i>European Radiology</i> , <b>2015</b> , 25, 2059-66	8	15
257	Hepatic steatosis in Wilson disease--Role of copper and PNPLA3 mutations. <i>Journal of Hepatology</i> , <b>2015</b> , 63, 156-63	13.4	74
256	High quality of screening colonoscopy in Austria is not dependent on endoscopist specialty or setting. <i>Endoscopy</i> , <b>2015</b> , 47, 207-16	3.4	17
255	Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH. <i>Digestive Diseases</i> , <b>2015</b> , 33, 598-607	3.2	27
254	Bile acid-induced cholemic nephropathy. <i>Digestive Diseases</i> , <b>2015</b> , 33, 367-75	3.2	42
253	Potential of nor-Ursodeoxycholic Acid in Cholestatic and Metabolic Disorders. <i>Digestive Diseases</i> , <b>2015</b> , 33, 433-9	3.2	31
252	New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. <i>Journal of Hepatology</i> , <b>2015</b> , 62, S25-37	13.4	306
251	1,25-(OH) <sub>2</sub> Vitamin D <sub>3</sub> prevents activation of hepatic stellate cells in vitro and ameliorates inflammatory liver damage but not fibrosis in the Abcb4(-/-) model. <i>Biochemical and Biophysical Research Communications</i> , <b>2015</b> , 459, 227-233	3.4	30
250	Tumor and Patient Characteristics of Individuals with Mismatch Repair Deficient Colorectal Cancer. <i>Digestion</i> , <b>2015</b> , 91, 286-93	3.6	7
249	New reliability criteria for transient elastography increase the number of accurate measurements for screening of cirrhosis and portal hypertension. <i>Liver International</i> , <b>2015</b> , 35, 381-90	7.9	90

248	A pilot study of the endomicroscopic assessment of tumor extension in Barrett's esophagus-associated neoplasia before endoscopic resection. <i>Endoscopy International Open</i> , <b>2015</b> , 3, E19-28	3	5
247	Forceps versus snare polypectomies in colorectal cancer screening: are we adhering to the guidelines?. <i>Endoscopy</i> , <b>2015</b> , 47, 898-902	3.4	19
246	Ubc9 Impairs Activation of the Brown Fat Energy Metabolism Program in Human White Adipocytes. <i>Molecular Endocrinology</i> , <b>2015</b> , 29, 1320-33		5
245	A greater proportion of liver transplant candidates have colorectal neoplasia than in the healthy screening population. <i>Clinical Gastroenterology and Hepatology</i> , <b>2015</b> , 13, 956-62	6.9	12
244	Serum alkaline phosphatase levels accurately reflect cholestasis in mice. <i>Hepatology</i> , <b>2015</b> , 62, 981-3	11.2	16
243	Pregnane X receptor activation and silencing promote steatosis of human hepatic cells by distinct lipogenic mechanisms. <i>Archives of Toxicology</i> , <b>2015</b> , 89, 2089-103	5.8	53
242	Growth hormone resistance exacerbates cholestasis-induced murine liver fibrosis. <i>Hepatology</i> , <b>2015</b> , 61, 613-26	11.2	22
241	Revisiting liver disease progression in HIV/HCV-coinfected patients: the influence of vitamin D, insulin resistance, immune status, IL28B and PNPLA3. <i>Liver International</i> , <b>2015</b> , 35, 876-85	7.9	29
240	The link between obesity and vitamin D in bariatric patients with omega-loop gastric bypass surgery - a vitamin D supplementation trial to compare the efficacy of postoperative cholecalciferol loading (LOAD): study protocol for a randomized controlled trial. <i>Trials</i> , <b>2015</b> , 16, 328	2.8	10
239	Bile acids and their receptors <b>2015</b> , 385-399		
238	Impact of acute kidney injury on prognosis of patients with liver cirrhosis and ascites: A retrospective cohort study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2015</b> , 30, 1657-65	4	33
237	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , <b>2015</b> , 61, 85-90	2.8	31
236	24-nor-ursodeoxycholic acid ameliorates inflammatory response and liver fibrosis in a murine model of hepatic schistosomiasis. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 871-8	13.4	46
235	Morphologic and Molecular Features of Hepatocellular Adenoma with Gadoteric Acid-enhanced MR Imaging. <i>Radiology</i> , <b>2015</b> , 277, 104-13	20.5	75
234	Performance of 2-D shear wave elastography in liver fibrosis assessment compared with serologic tests and transient elastography in clinical routine. <i>Ultrasound in Medicine and Biology</i> , <b>2015</b> , 41, 2340-9	3.5	20
233	Prognostic impact of ICG-PDR in patients with hypoxic hepatitis. <i>Annals of Intensive Care</i> , <b>2015</b> , 5, 47	8.9	9
232	Therapy of Primary Sclerosing Cholangitis--Today and Tomorrow. <i>Digestive Diseases</i> , <b>2015</b> , 33 Suppl 2, 149-63	3.2	26
231	Response-guided boceprevir-based triple therapy in HIV/HCV-coinfected patients: the HIVCOBOC-RGT study. <i>Journal of Infectious Diseases</i> , <b>2015</b> , 211, 729-35	7	9

230	Ursodeoxycholic acid exerts farnesoid X receptor-antagonistic effects on bile acid and lipid metabolism in morbid obesity. <i>Journal of Hepatology</i> , <b>2015</b> , 62, 1398-404	13.4	168
229	Efficacy of obeticholic acid in patients with primary biliary cirrhosis and inadequate response to ursodeoxycholic acid. <i>Gastroenterology</i> , <b>2015</b> , 148, 751-61.e8	13.3	381
228	Multicenter analysis of soluble Axl reveals diagnostic value for very early stage hepatocellular carcinoma. <i>International Journal of Cancer</i> , <b>2015</b> , 137, 385-394	7.5	34
227	Risk factors for development of spontaneous bacterial peritonitis and subsequent mortality in cirrhotic patients with ascites. <i>Liver International</i> , <b>2015</b> , 35, 2121-8	7.9	52
226	The Impact of PNPLA3 rs738409 SNP on Liver Fibrosis Progression, Portal Hypertension and Hepatic Steatosis in HIV/HCV Coinfection. <i>PLoS ONE</i> , <b>2015</b> , 10, e0143429	3.7	19
225	Endoscopic radiofrequency ablation for malignant biliary obstruction: a nationwide retrospective study of 84 consecutive applications. <i>Surgical Endoscopy and Other Interventional Techniques</i> , <b>2014</b> , 28, 854-60	5.2	129
224	The ART-strategy: sequential assessment of the ART score predicts outcome of patients with hepatocellular carcinoma re-treated with TACE. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 118-26	13.4	96
223	Health-related quality of life and severity of fatigue in HIV/HCV co-infected patients before, during, and after antiviral therapy with pegylated interferon plus ribavirin. <i>Liver International</i> , <b>2014</b> , 34, 69-77	7.9	25
222	The role of canalicular ABC transporters in cholestasis. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 546-60		56
221	How to STATE suitability and START transarterial chemoembolization in patients with intermediate stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 1287-96	13.4	104
220	Role of FDFT1 polymorphism for fibrosis progression in patients with chronic hepatitis C. <i>Liver International</i> , <b>2014</b> , 34, 388-95	7.9	14
219	Noninvasive differentiation of simple steatosis and steatohepatitis by using gadoxetic acid-enhanced MR imaging in patients with nonalcoholic fatty liver disease: a proof-of-concept study. <i>Radiology</i> , <b>2014</b> , 271, 739-47	20.5	53
218	SIRT1 controls liver regeneration by regulating bile acid metabolism through farnesoid X receptor and mammalian target of rapamycin signaling. <i>Hepatology</i> , <b>2014</b> , 59, 1972-83	11.2	90
217	Role of metabolic lipases and lipolytic metabolites in the pathogenesis of NAFLD. <i>Trends in Endocrinology and Metabolism</i> , <b>2014</b> , 25, 576-85	8.8	51
216	Therapeutic potential of and treatment with boceprevir/telaprevir-based triple-therapy in HIV/chronic hepatitis C co-infected patients in a real-world setting. <i>AIDS Patient Care and STDs</i> , <b>2014</b> , 28, 221-7	5.8	10
215	Adipocyte cell size, free fatty acids and apolipoproteins are associated with non-alcoholic liver injury progression in severely obese patients. <i>Metabolism: Clinical and Experimental</i> , <b>2014</b> , 63, 1542-52	12.7	75
214	Sex is a stronger predictor of colorectal adenoma and advanced adenoma than fecal occult blood test. <i>Medical Oncology</i> , <b>2014</b> , 31, 151	3.7	8
213	Application of localized $^{31}\text{P}$ MRS saturation transfer at 7 T for measurement of ATP metabolism in the liver: reproducibility and initial clinical application in patients with non-alcoholic fatty liver disease. <i>European Radiology</i> , <b>2014</b> , 24, 1602-9	8	21

212	EGFR has a tumour-promoting role in liver macrophages during hepatocellular carcinoma formation. <i>Nature Cell Biology</i> , <b>2014</b> , 16, 972-7	23.4	162
211	Role of adipose tissue in methionine-choline-deficient model of non-alcoholic steatohepatitis (NASH). <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2014</b> , 1842, 959-70	6.9	58
210	Clinical application of transcriptional activators of bile salt transporters. <i>Molecular Aspects of Medicine</i> , <b>2014</b> , 37, 57-76	16.7	42
209	Characterization of animal models for primary sclerosing cholangitis (PSC). <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1290-303	13.4	96
208	Von Willebrand factor antigen for detection of hepatopulmonary syndrome in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2014</b> , 61, 544-9	13.4	35
207	Lithocholic acid feeding results in direct hepato-toxicity independent of neutrophil function in mice. <i>Toxicology Letters</i> , <b>2014</b> , 228, 56-66	4.4	59
206	Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1135-42	13.4	30
205	Long-term outcomes of patients with Wilson disease in a large Austrian cohort. <i>Clinical Gastroenterology and Hepatology</i> , <b>2014</b> , 12, 683-9	6.9	97
204	Pharmacological correction of misfolding of ABC proteins. <i>Drug Discovery Today: Technologies</i> , <b>2014</b> , 12, e87-94	7.1	13
203	Comparative analysis and modeling of the severity of steatohepatitis in DDC-treated mouse strains. <i>PLoS ONE</i> , <b>2014</b> , 9, e111006	3.7	8
202	Inflammatory bowel disease alters intestinal bile acid transporter expression. <i>Drug Metabolism and Disposition</i> , <b>2014</b> , 42, 1423-31	4	55
201	Cystic fibrosis related liver disease--another black box in hepatology. <i>International Journal of Molecular Sciences</i> , <b>2014</b> , 15, 13529-49	6.3	37
200	Therapeutic role of bile acids and nuclear receptor agonists in fibrosing cholangiopathies. <i>Digestive Diseases</i> , <b>2014</b> , 32, 631-6	3.2	15
199	Epidemiological trends of hepatocellular carcinoma in Austria. <i>Digestive Diseases</i> , <b>2014</b> , 32, 664-9	3.2	9
198	The arachidonic acid metabolome serves as a conserved regulator of cholesterol metabolism. <i>Cell Metabolism</i> , <b>2014</b> , 20, 787-798	24.6	72
197	Incidence and mortality trends for biliary tract cancers in Austria. <i>Liver International</i> , <b>2014</b> , 34, 1102-8	7.9	23
196	Role of adipose triglyceride lipase (PNPLA2) in protection from hepatic inflammation in mouse models of steatohepatitis and endotoxemia. <i>Hepatology</i> , <b>2014</b> , 59, 858-69	11.2	61
195	Fibrate treatment for primary biliary cirrhosis. <i>Current Opinion in Gastroenterology</i> , <b>2014</b> , 30, 279-86	3	28



194	Alterations of canalicular ATP-binding cassette transporter expression in drug-induced liver injury. <i>Digestion</i> , <b>2014</b> , 90, 81-8	3.6	15
193	Bile acid receptors as targets for drug development. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2014</b> , 11, 55-67	24.2	423
192	Osteopontin is an initial mediator of inflammation and liver injury during obstructive cholestasis after bile duct ligation in mice. <i>Toxicology Letters</i> , <b>2014</b> , 224, 186-95	4.4	48
191	Nonselective $\beta$ blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. <i>Gastroenterology</i> , <b>2014</b> , 146, 1680-90.e1	13.3	257
190	Statin therapy is associated with reduced incidence of hypoxic hepatitis in critically ill patients. <i>Journal of Hepatology</i> , <b>2014</b> , 60, 1187-93	13.4	21
189	Strategies for assignment of HIV-HCV genotype-1-coinfected patients to either dual-therapy or direct-acting antiviral agent-based triple-therapy. <i>Antiviral Therapy</i> , <b>2014</b> , 19, 407-14	1.6	5
188	Proton pump inhibitor intake neither predisposes to spontaneous bacterial peritonitis or other infections nor increases mortality in patients with cirrhosis and ascites. <i>PLoS ONE</i> , <b>2014</b> , 9, e110503	3.7	43
187	Primary Sclerosing Cholangitis (PSC) <b>2014</b> , 301-316		
186	Nebivolol treatment increases splanchnic blood flow and portal pressure in cirrhotic rats via modulation of nitric oxide signalling. <i>Liver International</i> , <b>2013</b> , 33, 561-8	7.9	15
185	Differential effects of norUDCA and UDCA in obstructive cholestasis in mice. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 1201-8	13.4	72
184	Bile acids induce arrhythmias in human atrial myocardium--implications for altered serum bile acid composition in patients with atrial fibrillation. <i>Heart</i> , <b>2013</b> , 99, 1685-92	5.1	54
183	Animal Models of Cholestasis <b>2013</b> , 331-349		3
182	The ART of decision making: retreatment with transarterial chemoembolization in patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2013</b> , 57, 2261-73	11.2	230
181	PDX-1/Hes-1 interactions determine cholangiocyte proliferative response to injury in rodents: possible implications for sclerosing cholangitis. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 750-6	13.4	21
180	Bile acid transporters and regulatory nuclear receptors in the liver and beyond. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 155-68	13.4	257
179	Non-selective betablocker therapy decreases intestinal permeability and serum levels of LBP and IL-6 in patients with cirrhosis. <i>Journal of Hepatology</i> , <b>2013</b> , 58, 911-21	13.4	211
178	The PPAR $\alpha$ agonist fenofibrate suppresses B-cell lymphoma in mice by modulating lipid metabolism. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2013</b> , 1831, 1555-65	5	26
177	Bile acids as modulators of gut microbiota linking dietary habits and inflammatory bowel disease: a potentially dangerous liaison. <i>Gastroenterology</i> , <b>2013</b> , 144, 844-6	13.3	7



176	Mechanisms and functional consequences of liver failure substantially differ between endotoxaemia and faecal peritonitis in rats. <i>Liver International</i> , <b>2013</b> , 33, 283-93	7.9	16
175	Nuclear receptors as drug targets in cholestatic liver diseases. <i>Clinics in Liver Disease</i> , <b>2013</b> , 17, 161-89	4.6	76
174	Austrian consensus on the definition and treatment of portal hypertension and its complications (Billroth II). <i>Wiener Klinische Wochenschrift</i> , <b>2013</b> , 125, 200-19	2.3	36
173	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, 482-92	2.4	87
172	Single determination of C-reactive protein at the time of diagnosis predicts long-term outcome of patients with hepatocellular carcinoma. <i>Hepatology</i> , <b>2013</b> , 57, 2224-34	11.2	78
171	Hedgehog inhibition reduces angiogenesis by downregulation of tumoral VEGF-A expression in hepatocellular carcinoma. <i>United European Gastroenterology Journal</i> , <b>2013</b> , 1, 265-75	5.3	22
170	Bile acid-mediated control of liver triglycerides. <i>Seminars in Liver Disease</i> , <b>2013</b> , 33, 330-42	7.3	44
169	The liver in sepsis: patterns of response and injury. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 123-7	3.5	61
168	Hypoxic liver injury and cholestasis in critically ill patients. <i>Current Opinion in Critical Care</i> , <b>2013</b> , 19, 128-35	3.5	54
167	Bile acids trigger cholemic nephropathy in common bile-duct-ligated mice. <i>Hepatology</i> , <b>2013</b> , 58, 2056-69	11.2	104
166	Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. <i>Gut</i> , <b>2013</b> , 62, 1634-41	19.2	214
165	The impact of interleukin 28B rs12979860 single nucleotide polymorphism and liver fibrosis stage on response-guided therapy in HIV/HCV-coinfected patients. <i>Aids</i> , <b>2013</b> , 27, 2707-14	3.5	12
164	Low vitamin D levels are associated with impaired virologic response to PEGIFN + RBV therapy in HIV-hepatitis C virus coinfecting patients. <i>Aids</i> , <b>2013</b> , 27, 227-32	3.5	37
163	A4.6 Effects of Cholic Acid and its Derivatives in Experimental Arthritis. <i>Annals of the Rheumatic Diseases</i> , <b>2013</b> , 72, A25.2-A26	2.4	
162	Sulphatation does not appear to be a protective mechanism to prevent oxysterol accumulation in humans and mice. <i>PLoS ONE</i> , <b>2013</b> , 8, e68031	3.7	5
161	Genetic background effects of keratin 8 and 18 in a DDC-induced hepatotoxicity and Mallory-Denk body formation mouse model. <i>Laboratory Investigation</i> , <b>2012</b> , 92, 857-67	5.9	32
160	Selective activation of nuclear bile acid receptor FXR in the intestine protects mice against cholestasis. <i>Gastroenterology</i> , <b>2012</b> , 142, 355-65.e1-4	13.3	201
159	Identification of a novel Wilson disease gene mutation frequent in Upper Austria: a genetic and clinical study. <i>Journal of Human Genetics</i> , <b>2012</b> , 57, 564-7	4.3	18

158	Common genetic variation in vitamin D metabolism is associated with liver stiffness. <i>Hepatology</i> , <b>2012</b> , 56, 1883-91	11.2	44
157	Sedation in screening colonoscopy: impact on quality indicators and complications. <i>American Journal of Gastroenterology</i> , <b>2012</b> , 107, 1837-48	0.7	59
156	Association of 25-hydroxyvitamin D levels with liver dysfunction and mortality in chronic liver disease. <i>Liver International</i> , <b>2012</b> , 32, 845-51	7.9	81
155	The interaction of hepatic lipid and glucose metabolism in liver diseases. <i>Journal of Hepatology</i> , <b>2012</b> , 56, 952-64	13.4	549
154	Association of the IL28B genotype with insulin resistance in patients with chronic hepatitis C. <i>Journal of Hepatology</i> , <b>2012</b> , 57, 492-8	13.4	48
153	von Willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. <i>Hepatology</i> , <b>2012</b> , 56, 1439-47	11.2	116
152	Jaundice increases the rate of complications and one-year mortality in patients with hypoxic hepatitis. <i>Hepatology</i> , <b>2012</b> , 56, 2297-304	11.2	51
151	An In Silico Classification Model for Putative ABCC2 Substrates. <i>Molecular Informatics</i> , <b>2012</b> , 31, 547-553	3.8	15
150	Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury. <i>Gastroenterology</i> , <b>2012</b> , 142, 140-151.e12	13.3	114
149	Ursodeoxycholic acid in patients with chronic heart failure: a double-blind, randomized, placebo-controlled, crossover trial. <i>Journal of the American College of Cardiology</i> , <b>2012</b> , 59, 585-92	15.1	51
148	Primary sclerosing cholangitis: new approaches to diagnosis, surveillance and treatment. <i>Digestive Diseases</i> , <b>2012</b> , 30 Suppl 1, 39-47	3.2	24
147	Xenobiotic-induced liver injury and fibrosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , <b>2012</b> , 8, 571-80	5.5	16
146	Combined rifampicin and ursodeoxycholic acid treatment does not amplify rifampicin effects on hepatic detoxification and transport systems in humans. <i>Digestion</i> , <b>2012</b> , 86, 244-9	3.6	5
145	Absence of adipose triglyceride lipase protects from hepatic endoplasmic reticulum stress in mice. <i>Hepatology</i> , <b>2012</b> , 56, 270-80	11.2	57
144	Expression of the nuclear bile acid receptor/farnesoid X receptor is reduced in human colon carcinoma compared to nonneoplastic mucosa independent from site and may be associated with adverse prognosis. <i>International Journal of Cancer</i> , <b>2012</b> , 130, 2232-9	7.5	62
143	Noninvasive screening for liver fibrosis and portal hypertension by transient elastography--a large single center experience. <i>Wiener Klinische Wochenschrift</i> , <b>2012</b> , 124, 395-402	2.3	79
142	Hepatobiliary transporter expression and post-operative jaundice in patients undergoing partial hepatectomy. <i>Liver International</i> , <b>2012</b> , 32, 119-27	7.9	4
141	Evolving concepts in primary sclerosing cholangitis. <i>Liver International</i> , <b>2012</b> , 32, 352-69	7.9	20

140	Liver dysfunction and phosphatidylinositol-3-kinase signalling in early sepsis: experimental studies in rodent models of peritonitis. <i>PLoS Medicine</i> , <b>2012</b> , 9, e1001338	11.6	111
139	Animal models of biliary tract injury. <i>Current Opinion in Gastroenterology</i> , <b>2012</b> , 28, 239-43	3	9
138	A prospective evaluation of pulmonary, systemic and hepatic haemodynamics in HIV-HCV-coinfected patients before and after antiviral therapy with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , <b>2012</b> , 17, 1327-34	1.6	26
137	Liver transplantation: impaired biliary excretion of gadoxate is associated with an inferior 1-year retransplantation-free survival. <i>Investigative Radiology</i> , <b>2012</b> , 47, 353-8	10.1	31
136	Gene expression profiling unravels cancer-related hepatic molecular signatures in steatohepatitis but not in steatosis. <i>PLoS ONE</i> , <b>2012</b> , 7, e46584	3.7	69
135	Portal pressure predicts outcome and safety of antiviral therapy in cirrhotic patients with hepatitis C virus infection. <i>Clinical Gastroenterology and Hepatology</i> , <b>2011</b> , 9, 602-8.e1	6.9	53
134	Nuclear receptors as new perspective for the management of liver diseases. <i>Gastroenterology</i> , <b>2011</b> , 140, 1120-1125.e1-12	13.3	80
133	Will we ever model PSC? - "it's hard to be a PSC model!". <i>Clinics and Research in Hepatology and Gastroenterology</i> , <b>2011</b> , 35, 792-804	2.4	46
132	ATGL-mediated fat catabolism regulates cardiac mitochondrial function via PPAR- $\alpha$ and PGC-1. <i>Nature Medicine</i> , <b>2011</b> , 17, 1076-85	50.5	481
131	Pathogenesis of primary sclerosing cholangitis. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 727-39	2.5	77
130	Role of nuclear receptors for bile acid metabolism, bile secretion, cholestasis, and gallstone disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , <b>2011</b> , 1812, 867-78	6.9	62
129	Mouse mammary tumor virus in anti-mitochondrial antibody producing mouse models. <i>Journal of Hepatology</i> , <b>2011</b> , 55, 876-84	13.4	23
128	Adipose triglyceride lipase contributes to cancer-associated cachexia. <i>Science</i> , <b>2011</b> , 333, 233-8	33.3	357
127	Mycosis as a cause of secondary sclerosing cholangitis requiring liver retransplantation. <i>Transplantation</i> , <b>2011</b> , 91, e14-6	1.8	2
126	Histopathological diagnosis of non-alcoholic and alcoholic fatty liver disease. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , <b>2011</b> , 458, 511-23	5.1	91
125	Fibrosis in autoimmune and cholestatic liver disease. <i>Baillieres Best Practice and Research in Clinical Gastroenterology</i> , <b>2011</b> , 25, 245-58	2.5	54
124	Nuclear receptors in liver disease. <i>Hepatology</i> , <b>2011</b> , 53, 1023-34	11.2	197
123	Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/- (Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO <sub>3</sub> <sup>-</sup> output. <i>Hepatology</i> , <b>2011</b> , 54, 1303-12	11.2	167

122	Loss of CFTR affects biliary epithelium innate immunity and causes TLR4-NF- $\kappa$ B-mediated inflammatory response in mice. <i>Gastroenterology</i> , <b>2011</b> , 141, 1498-508, 1508.e1-5	13.3	95
121	Nor-ursodeoxycholic acid reverses hepatocyte-specific nemo-dependent steatohepatitis. <i>Gut</i> , <b>2011</b> , 60, 387-96	19.2	28
120	Sex-specific prevalence of adenomas, advanced adenomas, and colorectal cancer in individuals undergoing screening colonoscopy. <i>JAMA - Journal of the American Medical Association</i> , <b>2011</b> , 306, 1352-8	37.4	187
119	Targeting nuclear bile acid receptors for liver disease. <i>Digestive Diseases</i> , <b>2011</b> , 29, 98-102	3.2	22
118	Ursodeoxycholic acid for treatment of fatty liver disease and dyslipidemia in morbidly obese patients. <i>Digestive Diseases</i> , <b>2011</b> , 29, 117-8	3.2	6
117	Farnesoid X receptor represses hepatic human APOA gene expression. <i>Journal of Clinical Investigation</i> , <b>2011</b> , 121, 3724-34	15.9	75
116	Hepatobiliäre Funktionsstörungen und Leberversagen <b>2011</b> , 567-578		
115	The role of osteopontin and tumor necrosis factor alpha receptor-1 in xenobiotic-induced cholangitis and biliary fibrosis in mice. <i>Laboratory Investigation</i> , <b>2010</b> , 90, 844-52	5.9	33
114	Curcumin improves sclerosing cholangitis in Mdr2 <sup>-/-</sup> mice by inhibition of cholangiocyte inflammatory response and portal myofibroblast proliferation. <i>Gut</i> , <b>2010</b> , 59, 521-30	19.2	66
113	Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development. <i>Toxicological Sciences</i> , <b>2010</b> , 118, 485-500	4.4	269
112	The human UGT1A3 enzyme conjugates norursodeoxycholic acid into a C23-ester glucuronide in the liver. <i>Journal of Biological Chemistry</i> , <b>2010</b> , 285, 1113-21	5.4	18
111	New insights into autoimmune cholangitis through animal models. <i>Digestive Diseases</i> , <b>2010</b> , 28, 99-104	3.2	26
110	Nuclear receptor regulation of the adaptive response of bile acid transporters in cholestasis. <i>Seminars in Liver Disease</i> , <b>2010</b> , 30, 160-77	7.3	78
109	Signal transducer and activator of transcription 3 protects from liver injury and fibrosis in a mouse model of sclerosing cholangitis. <i>Gastroenterology</i> , <b>2010</b> , 138, 2499-508	13.3	61
108	Fatty liver and lipotoxicity. <i>Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids</i> , <b>2010</b> , 1801, 299-310	5	200
107	Low-dose atorvastatin improves dyslipidemia and vascular function in patients with primary biliary cirrhosis after one year of treatment. <i>Atherosclerosis</i> , <b>2010</b> , 209, 178-83	3.1	44
106	Bile acids as regulators of hepatic lipid and glucose metabolism. <i>Digestive Diseases</i> , <b>2010</b> , 28, 220-4	3.2	219
105	Serum gamma-glutamyl transferase and mortality in persons undergoing coronary angiography-The Ludwigshafen Risk and Cardiovascular Health Study. <i>Atherosclerosis</i> , <b>2010</b> , 208, 564-71	3.1	38

104	Nuclear receptors as drug targets in cholestasis and drug-induced hepatotoxicity. <i>Pharmacology &amp; Therapeutics</i> , <b>2010</b> , 126, 228-43	13.9	70
103	Disruption of the growth hormone--signal transducer and activator of transcription 5--insulinlike growth factor 1 axis severely aggravates liver fibrosis in a mouse model of cholestasis. <i>Hepatology</i> , <b>2010</b> , 51, 1319-26	11.2	42
102	Conjugation is essential for the anticholestatic effect of NorUrsodeoxycholic acid in tauroolithocholic acid-induced cholestasis in rat liver. <i>Hepatology</i> , <b>2010</b> , 52, 1758-68	11.2	32
101	Bile Acids and Their Receptors <b>2010</b> , 317-332		
100	Synthetic LXR agonist attenuates plaque formation in apoE-/- mice without inducing liver steatosis and hypertriglyceridemia. <i>Journal of Lipid Research</i> , <b>2009</b> , 50, 312-26	6.3	109
99	Hepatocyte nuclear factor-4alpha and bile acids regulate human concentrative nucleoside transporter-1 gene expression. <i>American Journal of Physiology - Renal Physiology</i> , <b>2009</b> , 296, G936-47	5.1	12
98	Side chain structure determines unique physiologic and therapeutic properties of norursodeoxycholic acid in Mdr2-/- mice. <i>Hepatology</i> , <b>2009</b> , 49, 1972-81	11.2	110
97	The role of the hepatocyte cytokeatin network in bile formation and resistance to bile acid challenge and cholestasis in mice. <i>Hepatology</i> , <b>2009</b> , 50, 893-9	11.2	9
96	Imbalance of pro- and antifibrogenic genes and bile duct injury in murine <i>Schistosoma mansoni</i> infection-induced liver fibrosis. <i>Tropical Medicine and International Health</i> , <b>2009</b> , 14, 1418-25	2.3	11
95	Nuclear receptors as therapeutic targets in cholestatic liver diseases. <i>British Journal of Pharmacology</i> , <b>2009</b> , 156, 7-27	8.6	115
94	Impact of experimental colitis on hepatobiliary transporter expression and bile duct injury in mice. <i>Liver International</i> , <b>2009</b> , 29, 1316-25	7.9	25
93	Evaluation of indocyanine green clearance and model for end-stage liver disease for estimation of short-term prognosis in decompensated cirrhosis. <i>Liver International</i> , <b>2009</b> , 29, 1516-20	7.9	29
92	When lightning strikes twice: the plot thickens for a dual role of the anion exchanger 2 (AE2/SLC4A2) in the pathogenesis and treatment of primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2009</b> , 50, 633-5	13.4	9
91	New molecular insights into the mechanisms of cholestasis. <i>Journal of Hepatology</i> , <b>2009</b> , 51, 565-80	13.4	196
90	Nuclear receptor ligands in therapy of cholestatic liver disease. <i>Frontiers in Bioscience - Landmark</i> , <b>2009</b> , 14, 4299-325	2.8	9
89	Farnesoid X receptor critically determines the fibrotic response in mice but is expressed to a low extent in human hepatic stellate cells and periductal myofibroblasts. <i>American Journal of Pathology</i> , <b>2009</b> , 175, 2392-405	5.8	124
88	Role of hepatic phospholipids in development of liver injury in Mdr2 (Abcb4) knockout mice. <i>Liver International</i> , <b>2008</b> , 28, 948-58	7.9	17
87	Validated comprehensive analytical method for quantification of coenzyme A activated compounds in biological tissues by online solid-phase extraction LC/MS/MS. <i>Analytical Chemistry</i> , <b>2008</b> , 80, 5736-42	7.8	42

86	Mechanisms of cholestasis. <i>Clinics in Liver Disease</i> , <b>2008</b> , 12, 1-26, vii	4.6	130
85	Ischemia and cholestasis: more than (just) the bile ducts!. <i>Transplantation</i> , <b>2008</b> , 85, 1083-5	1.8	8
84	Fatal hemobilia resulting from an iatrogenic arteriobiliary fistula as a rare complication of transjugular liver biopsy. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2008</b> , 20, 83-6	2.2	14
83	Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases. <i>Wiener Medizinische Wochenschrift</i> , <b>2008</b> , 158, 542-8	2.9	87
82	Clinical hepatotoxicity. Regulation and treatment with inducers of transport and cofactors. <i>Molecular Pharmaceutics</i> , <b>2007</b> , 4, 895-910	5.6	21
81	Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. <i>Gastroenterology</i> , <b>2007</b> , 132, 330-42	13.3	630
80	Atorvastatin in patients with primary biliary cirrhosis and incomplete biochemical response to ursodeoxycholic acid. <i>Hepatology</i> , <b>2007</b> , 46, 776-84	11.2	66
79	Expression of bile acid synthesis and detoxification enzymes and the alternative bile acid efflux pump MRP4 in patients with primary biliary cirrhosis. <i>Liver International</i> , <b>2007</b> , 27, 920-9	7.9	91
78	Extrahepatic cholestasis downregulates Oatp1 by TNF-alpha signalling without affecting Oatp2 and Oatp4 expression and sodium-independent bile salt uptake in rat liver. <i>Liver International</i> , <b>2007</b> , 27, 1056-85	7.8	17
77	Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , <b>2007</b> , 1773, 283-308	4.9	237
76	MDR3 (ABCB4) defects: a paradigm for the genetics of adult cholestatic syndromes. <i>Seminars in Liver Disease</i> , <b>2007</b> , 27, 77-98	7.3	153
75	Hepatobiliary transporter expression in intercellular adhesion molecule 1 knockout and Fas receptor-deficient mice after common bile duct ligation is independent of the degree of inflammation and oxidative stress. <i>Drug Metabolism and Disposition</i> , <b>2007</b> , 35, 1694-9	4	10
74	The importance of serum bile acid level analysis and treatment with ursodeoxycholic acid in intrahepatic cholestasis of pregnancy: a case series from central Europe. <i>Archives of Dermatology</i> , <b>2007</b> , 143, 757-62		31
73	Removal of bile acids by two different extracorporeal liver support systems in acute-on-chronic liver failure. <i>ASAIO Journal</i> , <b>2007</b> , 53, 187-93	3.6	39
72	A new xenobiotic-induced mouse model of sclerosing cholangitis and biliary fibrosis. <i>American Journal of Pathology</i> , <b>2007</b> , 171, 525-36	5.8	227
71	Bilirubin kinetic modeling for quantification of extracorporeal liver support. <i>Blood Purification</i> , <b>2006</b> , 24, 413-22	3.1	8
70	Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. <i>American Journal of Physiology - Renal Physiology</i> , <b>2006</b> , 290, G1124-30	5.1	218
69	Coordinated induction of bile acid detoxification and alternative elimination in mice: role of FXR-regulated organic solute transporter-alpha/beta in the adaptive response to bile acids. <i>American Journal of Physiology - Renal Physiology</i> , <b>2006</b> , 290, G923-32	5.1	141



68	Fxr(-/-) mice adapt to biliary obstruction by enhanced phase I detoxification and renal elimination of bile acids. <i>Journal of Lipid Research</i> , <b>2006</b> , 47, 582-92	6.3	87
67	Lithocholic acid feeding induces segmental bile duct obstruction and destructive cholangitis in mice. <i>American Journal of Pathology</i> , <b>2006</b> , 168, 410-22	5.8	134
66	24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , <b>2006</b> , 130, 465-81	13.3	250
65	Role of nuclear receptors in the adaptive response to bile acids and cholestasis: pathogenetic and therapeutic considerations. <i>Molecular Pharmaceutics</i> , <b>2006</b> , 3, 231-51	5.6	242
64	Mechanisms of disease: mechanisms and clinical implications of cholestasis in sepsis. <i>Nature Reviews Gastroenterology &amp; Hepatology</i> , <b>2006</b> , 3, 574-85		146
63	Successful treatment of severe unconjugated hyperbilirubinemia via induction of UGT1A1 by rifampicin. <i>Journal of Hepatology</i> , <b>2006</b> , 44, 243-5	13.4	29
62	Clinical-pathological conference series from the Medical University of Graz : case no. 131: elevated transaminases in a 30-year-old male. <i>Wiener Klinische Wochenschrift</i> , <b>2006</b> , 118, 769-75	2.3	0
61	Molecular mechanisms of cholestasis. <i>Wiener Medizinische Wochenschrift</i> , <b>2006</b> , 156, 380-5	2.9	52
60	Molecular regulation of hepatobiliary transport systems: clinical implications for understanding and treating cholestasis. <i>Journal of Clinical Gastroenterology</i> , <b>2005</b> , 39, S111-24	3	134
59	Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. <i>Gastroenterology</i> , <b>2005</b> , 129, 476-85	13.3	234
58	Oncosis represents the main type of cell death in mouse models of cholestasis. <i>Journal of Hepatology</i> , <b>2005</b> , 42, 378-85	13.4	74
57	In vivo quantification of liver dialysis: comparison of albumin dialysis and fractionated plasma separation. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 451-7	13.4	120
56	Mdr2 (Abcb4)-/- mice spontaneously develop severe biliary fibrosis via massive dysregulation of pro- and antifibrogenic genes. <i>Journal of Hepatology</i> , <b>2005</b> , 43, 1045-54	13.4	196
55	Complementary Stimulation of Hepatobiliary Transport and Detoxification Systems by Rifampicin and Ursodeoxycholic Acid in Humans. <i>Gastroenterology</i> , <b>2005</b> , 129, 476-485	13.3	201
54	Hepatobiliary transporter expression in human hepatocellular carcinoma. <i>Liver International</i> , <b>2005</b> , 25, 367-79	7.9	99
53	Cytokine-independent repression of rodent Ntcp in obstructive cholestasis. <i>Hepatology</i> , <b>2005</b> , 41, 470-7	11.2	36
52	CAR and PXR agonists stimulate hepatic bile acid and bilirubin detoxification and elimination pathways in mice. <i>Hepatology</i> , <b>2005</b> , 42, 420-30	11.2	257
51	Transcriptional regulation of hepatobiliary transport systems in health and disease: Implications for a rationale approach to the treatment of intrahepatic cholestasis. <i>Annals of Hepatology</i> , <b>2005</b> , 4, 77-99	3.1	36



50	Hepatotoxicity of NONI juice: report of two cases. <i>World Journal of Gastroenterology</i> , <b>2005</b> , 11, 4758-60	5.6	100
49	Cytokine-dependent regulation of hepatic organic anion transporter gene transactivators in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , <b>2005</b> , 289, G831-41	5.1	83
48	Role of nuclear receptors and hepatocyte-enriched transcription factors for Ntcp repression in biliary obstruction in mouse liver. <i>American Journal of Physiology - Renal Physiology</i> , <b>2005</b> , 289, G798-805	5.1	53
47	Pathophysiological role of poly(ADP-ribose) polymerase (PARP) activation during acetaminophen-induced liver cell necrosis in mice. <i>Toxicological Sciences</i> , <b>2005</b> , 84, 201-8	4.4	27
46	The keratin cytoskeleton in liver diseases. <i>Journal of Pathology</i> , <b>2004</b> , 204, 367-76	9.4	98
45	Spontaneous cholecysto- and hepatolithiasis in Mdr2 <sup>-/-</sup> mice: a model for low phospholipid-associated cholelithiasis. <i>Hepatology</i> , <b>2004</b> , 39, 117-28	11.2	127
44	The nuclear bile acid receptor FXR as a novel therapeutic target in cholestatic liver diseases: hype or hope?. <i>Hepatology</i> , <b>2004</b> , 40, 260-3	11.2	17
43	Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. <i>Gastroenterology</i> , <b>2004</b> , 127, 261-74	13.3	456
42	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2004</b> , 20, 220-30	3	26
41	Acquired Alterations of Transporter Expression and Function in Cholestasis		1
40	Successful conservative management of acute hepatic failure following exertional heatstroke. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2003</b> , 15, 1135-9	2.2	15
39	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2003</b> , 19, 216-31	3	8
38	Bile salt transporters: molecular characterization, function, and regulation. <i>Physiological Reviews</i> , <b>2003</b> , 83, 633-71	47.9	775
37	Role of farnesoid X receptor in determining hepatic ABC transporter expression and liver injury in bile duct-ligated mice. <i>Gastroenterology</i> , <b>2003</b> , 125, 825-38	13.3	235
36	When bile ducts say NO: the good, the bad, and the ugly. <i>Gastroenterology</i> , <b>2003</b> , 124, 847-51	13.3	16
35	Molecular aspects of bile formation and cholestasis. <i>Trends in Molecular Medicine</i> , <b>2003</b> , 9, 558-64	11.5	82
34	Down-regulation of the Na <sup>+</sup> /taurocholate cotransporting polypeptide during pregnancy in the rat. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 148-55	13.4	36
33	Mallory body formation in primary biliary cirrhosis is associated with increased amounts and abnormal phosphorylation and ubiquitination of cytokeratins. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 387-94	13.4	43

32	Anti-tumor necrosis factor-alpha monoclonal antibody therapy in severe alcoholic hepatitis. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 419-25	13.4	176
31	Adaptive changes in hepatobiliary transporter expression in primary biliary cirrhosis. <i>Journal of Hepatology</i> , <b>2003</b> , 38, 717-27	13.4	241
30	Role of nuclear bile acid receptor, FXR, in adaptive ABC transporter regulation by cholic and ursodeoxycholic acid in mouse liver, kidney and intestine. <i>Journal of Hepatology</i> , <b>2003</b> , 39, 480-8	13.4	159
29	Induction of short heterodimer partner 1 precedes downregulation of Ntcp in bile duct-ligated mice. <i>American Journal of Physiology - Renal Physiology</i> , <b>2002</b> , 282, G184-91	5.1	59
28	Hepatic transport systems. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>2002</b> , 17 Suppl, S105-12		20
27	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2002</b> , 18, 314-29	3	6
26	Bile acid-induced Mallory body formation in drug-primed mouse liver. <i>American Journal of Pathology</i> , <b>2002</b> , 161, 2019-26	5.8	41
25	Cytokeratins as targets for bile acid-induced toxicity. <i>American Journal of Pathology</i> , <b>2002</b> , 160, 491-9	5.8	39
24	Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. <i>Gastroenterology</i> , <b>2002</b> , 123, 1238-51	13.3	249
23	Alterations of hepatobiliary transporter expression in primary biliary cirrhosis (PBC). <i>Journal of Hepatology</i> , <b>2002</b> , 36, 28-29	13.4	2
22	Hepatobiliary transporter expression in percutaneous liver biopsies of patients with cholestatic liver diseases. <i>Hepatology</i> , <b>2001</b> , 33, 633-46	11.2	276
21	No evidence for mutagenic effects of ribavirin: report of two normal pregnancies. <i>American Journal of Gastroenterology</i> , <b>2001</b> , 96, 2286-7	0.7	28
20	Abnormal hepatic sinusoidal bile acid transport: new insights into the pathogenesis of cholestasis?. <i>Gastroenterology</i> , <b>2001</b> , 120, 321-3	13.3	1
19	Effects of ursodeoxycholic and cholic acid feeding on hepatocellular transporter expression in mouse liver. <i>Gastroenterology</i> , <b>2001</b> , 121, 170-83	13.3	236
18	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2001</b> , 17, 242-56	3	9
17	Intra-hepatic haematoma complicating transjugular intra-hepatic portosystemic shunt for Budd-Chiari syndrome associated with anti-phospholipid antibodies, aplastic anaemia and chronic hepatitis C. <i>European Journal of Gastroenterology and Hepatology</i> , <b>2000</b> , 12, 813-6	2.2	15
16	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>2000</b> , 16, 239-50	3	
15	Hepatocellular bile salt transport: lessons from cholestasis. <i>Canadian Journal of Gastroenterology &amp; Hepatology</i> , <b>2000</b> , 14 Suppl D, 99D-104D		6

14	Expression of the bile salt export pump is maintained after chronic cholestasis in the rat. <i>Gastroenterology</i> , <b>2000</b> , 118, 163-72	13.3	222
13	Inflammation-induced cholestasis. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , <b>1999</b> , 14, 946-59	13.4	175
12	Molecular regulation of hepatocellular transport systems in cholestasis. <i>Journal of Hepatology</i> , <b>1999</b> , 31, 165-78	13.4	131
11	Cholestatic syndromes. <i>Current Opinion in Gastroenterology</i> , <b>1999</b> , 15, 217-28	3	2
10	Vasopressin reverses mesenteric hyperemia and vasoconstrictor hyporesponsiveness in anesthetized portal hypertensive rats. <i>Hepatology</i> , <b>1998</b> , 28, 646-54	11.2	16
9	Maternal cholestasis does not affect the ontogenic pattern of expression of the Na <sup>+</sup> /taurocholate cotransporting polypeptide (ntcp) in the fetal and neonatal rat liver. <i>Hepatology</i> , <b>1998</b> , 28, 789-95	11.2	21
8	Neither intestinal sequestration of bile acids nor common bile duct ligation modulate the expression and function of the rat ileal bile acid transporter. <i>Hepatology</i> , <b>1998</b> , 28, 1081-7	11.2	64
7	Nitric oxide and guanosine 3',5'-cyclic monophosphate stimulate bile secretion in isolated rat hepatocyte couplets, but not in isolated bile duct units. <i>Hepatology</i> , <b>1998</b> , 28, 1621-8	11.2	24
6	Role of glutathione in hepatic bile formation during reperfusion after cold ischemia of the rat liver. <i>Journal of Hepatology</i> , <b>1998</b> , 28, 812-9	13.4	24
5	Molecular pathogenesis of cholestasis. <i>New England Journal of Medicine</i> , <b>1998</b> , 339, 1217-27	59.2	645
4	Successful steroid treatment of idiopathic thrombocytopenic purpura after orthotopic liver transplantation for primary biliary cirrhosis. <i>American Journal of Gastroenterology</i> , <b>1998</b> , 93, 1985-6	0.7	6
3	Inhibition of nitric oxide synthesis in ischemia/reperfusion of the rat liver is followed by impairment of hepatic microvascular blood flow. <i>Journal of Hepatology</i> , <b>1997</b> , 27, 163-9	13.4	70
2	Endoscopic intracorporeal laser lithotripsy of difficult common bile duct stones with a stone-recognition pulsed dye laser system. <i>Gastrointestinal Endoscopy</i> , <b>1995</b> , 42, 416-9	5.2	43
1	Beyond PXR and CAR, Regulation of Xenobiotic Metabolism by other Nuclear Receptors	275-300	